Clinical Trial

A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-21.
Trial Details
NCT Number NCT07614022
Lead Sponsor Wake Forest University Health Sciences
Collaborators: Newave Pharmaceutical Inc, Atrium Health Wake Forest Baptist, National Cancer Institute (NCI)
Conditions Philadelphia Positive Acute Lymphoblastic Leukemia
Enrollment 26 participants
Start Date 2026-10
Primary Completion 2030-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-05